Indication
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
1 clinical trial
7 products
Product
PonatinibProduct
ImatinibClinical trial
A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)Status: Active (not recruiting), Estimated PCD: 2022-08-12
Product
DexamethasoneProduct
MethotrexateProduct
VincristineProduct
CytarabineProduct
Prednisone